 Brooke Bredbeck
Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Surgeons | 2 | 2022 | 341 | 0.990 |
Why?
| | Sentinel Lymph Node | 3 | 2023 | 49 | 0.990 |
Why?
| | Lymph Node Excision | 5 | 2023 | 173 | 0.880 |
Why?
| | Breast Neoplasms | 5 | 2022 | 2365 | 0.770 |
Why?
| | Melanoma | 4 | 2023 | 757 | 0.750 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2022 | 28 | 0.710 |
Why?
| | Liposarcoma | 1 | 2022 | 31 | 0.700 |
Why?
| | Soft Tissue Neoplasms | 1 | 2022 | 128 | 0.650 |
Why?
| | Intersectoral Collaboration | 1 | 2021 | 64 | 0.640 |
Why?
| | Skin Neoplasms | 3 | 2023 | 850 | 0.610 |
Why?
| | Sarcoma | 1 | 2022 | 203 | 0.590 |
Why?
| | Tumor Burden | 1 | 2020 | 324 | 0.580 |
Why?
| | Research Personnel | 1 | 2021 | 185 | 0.570 |
Why?
| | Mastectomy | 3 | 2022 | 174 | 0.470 |
Why?
| | Sentinel Lymph Node Biopsy | 5 | 2023 | 117 | 0.450 |
Why?
| | Pancreaticojejunostomy | 1 | 2015 | 8 | 0.450 |
Why?
| | Duodenum | 1 | 2015 | 77 | 0.430 |
Why?
| | Databases, Factual | 1 | 2020 | 1494 | 0.420 |
Why?
| | Pancreas | 1 | 2015 | 341 | 0.360 |
Why?
| | Epigenesis, Genetic | 1 | 2015 | 669 | 0.320 |
Why?
| | Hospitals, Rural | 2 | 2026 | 50 | 0.290 |
Why?
| | Colorectal Neoplasms | 1 | 2015 | 849 | 0.250 |
Why?
| | Axilla | 2 | 2021 | 51 | 0.220 |
Why?
| | Surgical Procedures, Operative | 1 | 2026 | 272 | 0.200 |
Why?
| | Humans | 21 | 2026 | 144671 | 0.180 |
Why?
| | Organizations | 1 | 2022 | 27 | 0.180 |
Why?
| | Mentors | 2 | 2022 | 214 | 0.180 |
Why?
| | Sexual Harassment | 1 | 2022 | 28 | 0.180 |
Why?
| | Demography | 1 | 2022 | 287 | 0.170 |
Why?
| | Inpatients | 1 | 2026 | 547 | 0.170 |
Why?
| | Rural Population | 1 | 2026 | 657 | 0.170 |
Why?
| | Unilateral Breast Neoplasms | 1 | 2021 | 4 | 0.170 |
Why?
| | Prophylactic Mastectomy | 1 | 2021 | 10 | 0.170 |
Why?
| | Quality of Health Care | 1 | 2026 | 692 | 0.160 |
Why?
| | Breast | 1 | 2021 | 157 | 0.160 |
Why?
| | Costs and Cost Analysis | 1 | 2021 | 221 | 0.160 |
Why?
| | Michigan | 1 | 2021 | 137 | 0.160 |
Why?
| | Medicare | 1 | 2026 | 899 | 0.160 |
Why?
| | Efficiency | 1 | 2021 | 104 | 0.160 |
Why?
| | Female | 13 | 2026 | 78304 | 0.160 |
Why?
| | Patient Preference | 1 | 2022 | 226 | 0.160 |
Why?
| | Disease-Free Survival | 1 | 2022 | 768 | 0.160 |
Why?
| | General Surgery | 1 | 2022 | 206 | 0.150 |
Why?
| | Retrospective Studies | 6 | 2026 | 17149 | 0.150 |
Why?
| | Mentoring | 1 | 2022 | 164 | 0.150 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1465 | 0.130 |
Why?
| | Students, Medical | 1 | 2022 | 374 | 0.130 |
Why?
| | Aged | 6 | 2026 | 25955 | 0.130 |
Why?
| | Injury Severity Score | 2 | 2016 | 602 | 0.120 |
Why?
| | Lectins | 1 | 2016 | 45 | 0.120 |
Why?
| | Hypotension | 1 | 2016 | 126 | 0.110 |
Why?
| | Shock | 1 | 2016 | 108 | 0.110 |
Why?
| | Chimerism | 1 | 2015 | 34 | 0.110 |
Why?
| | Burnout, Professional | 1 | 2022 | 483 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1145 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2016 | 139 | 0.110 |
Why?
| | Parity | 1 | 2015 | 108 | 0.110 |
Why?
| | Aged, 80 and over | 3 | 2026 | 8284 | 0.110 |
Why?
| | Adult | 7 | 2023 | 40489 | 0.100 |
Why?
| | Adiponectin | 1 | 2016 | 240 | 0.100 |
Why?
| | Postoperative Complications | 1 | 2026 | 2950 | 0.100 |
Why?
| | Fibrosis | 1 | 2016 | 547 | 0.100 |
Why?
| | Wounds, Nonpenetrating | 1 | 2016 | 321 | 0.100 |
Why?
| | Child | 3 | 2022 | 22600 | 0.090 |
Why?
| | Metabolic Syndrome | 1 | 2016 | 354 | 0.090 |
Why?
| | Pandemics | 1 | 2021 | 1700 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1360 | 0.090 |
Why?
| | Prognosis | 1 | 2020 | 4312 | 0.090 |
Why?
| | Adipose Tissue | 1 | 2016 | 643 | 0.090 |
Why?
| | Internship and Residency | 1 | 2022 | 1262 | 0.080 |
Why?
| | Mastectomy, Segmental | 2 | 2021 | 107 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5414 | 0.080 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5870 | 0.080 |
Why?
| | Prospective Studies | 2 | 2020 | 7994 | 0.080 |
Why?
| | Survival Rate | 1 | 2015 | 2089 | 0.080 |
Why?
| | Hypoglycemic Agents | 2 | 2016 | 1388 | 0.070 |
Why?
| | Sex Factors | 1 | 2015 | 2104 | 0.070 |
Why?
| | Hypoxia | 1 | 2016 | 1193 | 0.070 |
Why?
| | Cytokines | 1 | 2016 | 2045 | 0.070 |
Why?
| | Child, Preschool | 2 | 2020 | 11790 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2016 | 1241 | 0.060 |
Why?
| | Middle Aged | 5 | 2021 | 35971 | 0.060 |
Why?
| | Young Adult | 2 | 2020 | 14122 | 0.060 |
Why?
| | Insulin | 1 | 2016 | 2502 | 0.050 |
Why?
| | Inflammation | 1 | 2016 | 2870 | 0.050 |
Why?
| | Decision Making | 2 | 2022 | 973 | 0.050 |
Why?
| | Adolescent | 2 | 2020 | 22409 | 0.050 |
Why?
| | Male | 5 | 2026 | 72431 | 0.050 |
Why?
| | Obesity | 1 | 2016 | 3070 | 0.050 |
Why?
| | Hospital Mortality | 1 | 2026 | 1033 | 0.040 |
Why?
| | Esophagectomy | 1 | 2022 | 135 | 0.040 |
Why?
| | Patient Readmission | 1 | 2026 | 765 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2022 | 220 | 0.040 |
Why?
| | Length of Stay | 1 | 2026 | 1339 | 0.040 |
Why?
| | Cohort Studies | 2 | 2023 | 5957 | 0.040 |
Why?
| | Pancreatectomy | 1 | 2022 | 286 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2022 | 707 | 0.030 |
Why?
| | Program Evaluation | 1 | 2022 | 941 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 729 | 0.030 |
Why?
| | United States | 2 | 2026 | 16018 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2016 | 81 | 0.030 |
Why?
| | Waist Circumference | 1 | 2016 | 141 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 401 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 2016 | 323 | 0.020 |
Why?
| | Administration, Oral | 1 | 2016 | 851 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2016 | 405 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3414 | 0.020 |
Why?
| | Registries | 1 | 2021 | 2392 | 0.020 |
Why?
| | Body Weight | 1 | 2016 | 968 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2019 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2016 | 2033 | 0.020 |
Why?
| | Lipids | 1 | 2016 | 706 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1766 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3329 | 0.020 |
Why?
| | Blood Glucose | 1 | 2016 | 2326 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 11735 | 0.010 |
Why?
|
|
Bredbeck's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|